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A Mouse Model of Autoimmune 
Cholangitis via Syngeneic Bile Duct 
Protein Immunization
Wen-Tao Ma1,2,3, Qing-Zhi Liu1,2, Jing-Bo Yang2, Yan-Qing Yang2, Zhi-Bin Zhao1,2, Hong-Di 
Ma2, M. Eric Gershwin4 & Zhe-Xiong Lian1,2,5
Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by the destruction of 
interlobular biliary ductules, which progressively leads to cholestasis, hepatic fibrosis, cirrhosis, and 
eventually liver failure. Several mouse models have been used to clarify the pathogenesis of PBC and 
are generally considered reflective of an autoimmune cholangitis. Most models focus on issues of 
molecular mimicry between the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the 
major mitochondrial autoantigen of PBC and xenobiotic cross reactive chemicals. None have focused 
on the classic models of breaking tolerance, namely immunization with self-tissue. Here, we report 
a novel mouse model of autoimmune cholangitis via immunization with syngeneic bile duct protein 
(BDP). Our results demonstrate that syngeneic bile duct antigens efficiently break immune tolerance of 
recipient mice, capturing several key features of PBC, including liver-specific inflammation focused on 
portal tract areas, increased number and activation state of CD4 and CD8 T cells in the liver and spleen. 
Furthermore, the germinal center (GC) responses in the spleen were more enhanced in our mouse 
model. Finally, these mice were 100% positive for anti-mitochondrial antibodies (AMAs). In conclusion, 
we developed a novel mouse model of PBC that may help to elucidate the detailed mechanism of this 
complex disease.
Primary biliary cholangitis (PBC) is a prototypical autoimmune liver disease particularly affecting middle-aged 
women1–3. The characteristic histological features of PBC are the destruction of small bile ducts in the portal 
tracts, biliary epithelial cell apoptosis, and progressive bile duct loss1,4. Inflammatory cells aggregate around the 
injured bile ducts4. Despite intense genetic, epigenetic, and immunologic analysis, the etiology of PBC remains 
enigmatic5–9. The bile duct injury results in impaired bile secretion and intrahepatic cholestasis, which fur-
ther lead to hepatic damage, fibrosis, and eventually cirrhosis or liver failure1. Indeed the bile acids themselves 
may promote inflammation10. Serobiochemically, 90–95% of PBC patients are positive for anti-mitochondrial 
antibodies (AMAs), which predominantly recognize the E2 subunit of the pyruvate dehydrogenase complex 
(PDC-E2) and, in some cases, the E2 subunit of branched chain 2-oxo-acid dehydrogenase (BCOADC-E2) and 
2-oxo-glutarate dehydrogenase (OGDC-E2)1,11. These autoantibodies may cross react with both microbial and 
environmental products12–14. Immunologically, the levels of various inflammatory cytokines, such as interleukin 
(IL)-12 and interferon (IFN)-γ, are increased in the serum of PBC patients15,16. It is unclear why the immune 
attack is predominantly liver-specific, because autoantigens are detected in all nucleated cells. In an effort to 
investigate the pathogenesis of PBC, several mouse models have been developed. The dominant-negative trans-
forming growth factor-β receptor II (dnTGFβRII) mouse, which was first reported by our group in 2006, has 
been extensively investigated as a PBC model17. This model shares several histological and serological similarities 
with human PBC, such as bile duct injury, inflammatory cell infiltration in portal tracts, and AMA positivity17–19. 
IL-2Rα−/− mice constitute another model developed by our group, which exhibits the appearance of AMAs, 
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portal inflammation, abnormal T cell activation, and increased inflammatory cytokine levels in the serum18,20,21. 
Furthermore, 2-octynoic acid-BSA (2-OA-BSA)-immunized mice22, N. aromaticivorans-infected mice23, E. 
coli-infected mice24, and our recently developed IL-12p40−/−CD25−/− mice25 have also been used to investigate 
the pathogenesis of PBC.
Here, we report the establishment of an additional PBC mouse model induced via syngeneic bile duct pro-
tein (BDP) immunization that captures several typical features of PBC patients. Our mouse model exhibits a 
liver-specific inflammation profile, with lymphocyte infiltration in areas of the portal tracts. Furthermore, these 
mice exhibit more activated T cells in the liver and spleen, and demonstrate enhanced germinal center (GC) 
responses in the spleen. In particular, increased levels of AMAs, including AMAs against PDC-E2, BCOADC-E2, 
and OGDC-E2, were identified in the serum of our mouse model. Our results highlight the critical role of bile 
duct antigens in the pathogenesis of this enigmatic disease.
Results
BDP immunization triggers a liver-specific inflammatory response. Compared with the mice 
immunized with adjuvant alone or adjuvant emulsified with small intestinal epithelial cell protein (SIEP), the 
mice immunized with BDP exhibited a liver-specific inflammation profile (Figs 1a–g and S1a–g), which was 
evidenced by a significantly increased liver mono-nuclear cell (MNC) number (p = 0.0043, Fig. 1a), increased 
MNC density in the liver (p = 0.0087, Fig. 1b), and higher MNC number in the liver draining lymph nodes 
(dLNs) (p = 0.0411, Fig. 1c). We also determined that the spleen MNC number and spleen weight were increased 
after BDP immunization (p = 0.0152 for the spleen MNC number, p = 0.0048 for the spleen weight, Fig. 1d,e). 
Moreover, the spleen MNC number and spleen weight were positively correlated with liver MNC number 
(Fig. 1h,i). In contrast, BDP immunization had no obvious effects on the inflammation of the mesenteric lymph 
nodes (mLNs) (Fig. 1f) or peripheral lymph nodes (pLNs) (Fig. 1g).
BDP immunization triggered more severe liver-specific inflammatory infiltration around the 
bile ducts. In contrast with the control adjuvant-treated mice, which exhibited minimal inflammation in 
the liver, BDP immunization triggered evident inflammation in the liver, and the inflammation areas were 
mainly focused on the portal tracts (Fig. 2a). In accordance with this finding, immunohistochemical staining 
of cytokerin-19 (CK-19), which comprised a specific marker for biliary epithelial cells (BECs)26, demonstrated 
that the inflammatory cells were mainly located around CK-19-positive BECs (Fig. 2b). In contrast, there was no 
inflammation in other tissues, such as the heart, kidney, lung, pancreas, or salivary gland (Fig. S2a–d). However, 
no granulomas or bile duct damage were observed in both adjuvant- and BDP-treated mice.
Increases in T and DC cell subsets with a decrease in regulatory T cell (Treg) percentage after 
BDP immunization. We further analyzed the specific inflammatory cell subsets in the liver, and determined 
that the number of T cells, including CD4 and CD8 T cell subsets, significantly increased in the BDP-treated 
mice compared with the control mice (p = 0.0161 for the liver T cell number, p = 0.0280 for the liver CD4 T cell 
number, p = 0.0208 for the liver CD8 T cell number, Fig. 3a). In accordance with these findings, in the spleen, 
the number of total T cells, and CD4 T cell subset as well as CD8 T cell subset, also increased significantly in the 
BDP-treated mice (p = 0.0260 for the spleen T cell number, p = 0.0152 for the spleen CD4 T cell number, and 
p = 0.0260 for the spleen CD8 T cell number, Fig. 3b). Interestingly, dendritic cells (DCs), which comprised pro-
fessional antigen-presenting cells for T cells, were also increased in number in the liver and spleen (p = 0.0048 for 
the liver DC number and p = 0.0411 for the spleen DC number, Fig. 3a,b). In contrast with the increased T cell 
number in the liver and spleen in BDP-treated mice, the Treg percentages were significantly decreased in these 
mice in the liver (p = 0.0087, Fig. 3c) and spleen (p = 0.0022, Fig. 3d) compared with the control mice.
More activated phenotype of CD4 and CD8 T cells in the liver after BDP immunization. Based 
on the increased T cell number results after BDP immunization, we subsequently analyzed the phenotypes of 
liver and spleen T cells. We determined that in the liver, both the CD4 and CD8 T cell subsets exhibited a more 
activated phenotype, which was reflected by the increased percentages of memory cells, and the decreased per-
centages of naïve cells (p = 0.0003 for liver effector memory CD4 T cells, p = 0.0002 for liver naïve CD4 T cells, 
p = 0.0028 for liver effector memory CD8 T cells, p = 0.0031 for liver naïve CD8 T cells, Fig. 4a). In accord-
ance with these findings, the CD4 and CD8 T cells demonstrated a stronger ability to secrete the inflammatory 
cytokine IFN-γ (p = 0.0244 for liver IFN-γ+ CD4 T cells and p = 0.0038 for liver IFN-γ+ CD8 T cells, Fig. 4b). 
Interestingly, the CD4 T cells in the spleen also exhibited a more enhanced activation state (p = 0.0003 for spleen 
effector memory CD4 T cells, p = 0.0002 for spleen naïve CD4 T cells). In contrast, CD8 T cell activation profiles 
in the spleen were not significantly different (Fig. S3a). In addition, IFN-γ secreting ability of both splenic CD4 or 
CD8 T cells did not show significant differences (Fig. S3b) after BDP immunization.
Enhanced GC response in the spleen after BDP immunization. We subsequently demonstrated that 
the GC responses were more enhanced in the BDP-treated mice than in the control mice, and this finding was 
evidenced by a significantly increased GC B cell percentage and number (p = 0.0043 for GC B-cell percentage, 
p = 0.0087 for GC B-cell number, Fig. 5a,b), and an increased plasmablast percentage and number (p = 0.0471 for 
plasmablast cell percentage, and p = 0.0173 for plasmablast cell number, Fig. 5c,d) in the spleens of BDP-treated 
mice than in the control mice.
Increased serum AMA levels after BDP immunization. Considering the increase in the splenic 
GC responses, we further analyzed the AMA profiles in our mouse model, and the results indicated that BDP 
immunization triggered significantly elevated levels of serum AMAs against PDC-E2 (p = 0.0043, Fig. 6a), 
BCOADC-E2 (p = 0.0069, Fig. 6b), and OGDC-E2 (p = 0.0048, Fig. 6c) compared with the control mice.
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Discussion
In PBC patients, a typical histological feature is the progressive destruction of small bile ducts, which may lead to 
the disappearance of bile ducts and ultimately liver fibrosis and, in some cases, may progress to liver cirrhosis or 
liver failure. It is known that BECs line the lumen of the intra-hepatic bile ducts and contribute to bile secretion 
via the release of bicarbonate and water27. Interestingly, BECs are also immunologically functional. They express 
several Toll-like receptors, death receptors, and human leukocyte antigen Class II, which help them to present 
antigens and secrete inflammatory cytokines. For example, BECs are capable of secreting IL-6, IL-23, and IL-1β 
to facilitate the differentiation of Th17 cells28. Moreover, death receptor 5 (DR5) expression on BECs contributes 
to common bile-duct ligation-induced cholestasis in mice, and DR5-mediated signaling is also indicated to be 
involved in the pathogenesis of human cholestatic diseases, such as primary sclerosing cholangitis and PBC29. 
Importantly, apoptotic BECs from PBC patients are positive for autoantigen PDC-E2, and this is reactive with 
Figure 1. BDP immunization triggered a liver-specific inflammatory response. (a–g) Total MNC numbers in 
the liver (a), liver dLNs (c), spleen (d), mLNs (f), and pLNs (g), as well as the liver MNC density (b) and spleen 
weight (e) were compared between adjuvant- (Adju) (n = 6) and BDP-treated groups (n = 6). (h,i) Linear 
regression analysis of spleen MNC number and spleen weight versus liver MNC number.
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AMA-containing serum, and is capable of activating the immune system to secrete inflammatory cytokines30,31. 
In our mouse model, it is likely that auto-antigens in BDP break down tolerance and initiate the inflammatory 
responses. The BECs may have, in turn, become the target of the activated immune cells, which aggravated the 
liver inflammatory response. Moreover, SIEP immunization did not trigger liver inflammation, which was as 
expected because there was no small intestine-specific antigen in the liver. SIEP immunization also did not trigger 
inflammation in the intestine, which may indicate that intestinal tolerance is more difficult to break down than 
that of the liver. We highlighted the theory of tolerance breakdown by the activation of autoimmune lymphocytes 
via auto-antigens, which was different from genetic mutation-induced autoimmune liver disease in dnTGFβRII 
mice, IL-2Rα−/− mice and IL-2Rα−/−p40−/− mice, and also differed from xenobiotic- or infection-induced auto-
immune liver disease in 2-OA-BSA-immunized mice22, N. aromaticivorans-infected mice23, and E. coli-infected 
mice24.
Several studies suggested that the prevalence of PBC development varies by geographic areas32, and envi-
ronmental toxins, such as volatile aromatic hydrocarbons and trichloroethylene, were significantly associated 
with a cluster of PBC patients in New York33, which suggests the importance of environmental factors for PBC 
induction34. Moreover, the higher risk for the development of PBC in first-degree relatives35,36, particularly the 
higher concordance rate of PBC in monozygotic compared with dizygotic twins37, also indicated the critical 
Figure 2. BDP immunization triggered more severe inflammatory infiltration around bile ducts. (a) H&E 
staining of liver sections of adjuvant- (Adju) and BDP-treated mice. (b) CK-19 immunohistochemical staining 
of liver sections from adjuvant- (Adju) and BDP-treated mice.
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role of genetic predisposition in this disease. Thus, the pathogenesis of PBC included a combination of envi-
ronmental factors and genetic predisposition. In the present study, the development of the mouse model was 
predominantly dependent on bile duct antigens, which in humans may reflect environmental factors that may 
be mediated by molecular mimicry, and which is similar with the case in 2-OA-BSA-immunized mice22, N. 
Figure 3. Increases in T and DC cell subsets with a decrease in Treg percentage after BDP immunization. 
(a,b) Total numbers of T cells (CD3+NK1.1−), CD4 T cells (CD3+NK1.1−CD4+CD8−), CD8 T cells 
(CD3+NK1.1−CD8+CD4−), and DCs (CD3−NK1.1−CD11chighMHCIIhigh) in the liver (a) and spleen (b) from 
adjuvant- (Adju) (n = 8) and BDP-treated mice (n = 9). (c,d) Percentages of CD3+CD4+NK1.1−Foxp3+ Treg 
cells in CD3+CD4+NK1.1− cells in the liver (c) and spleen (d) from adjuvant- (Adju) (n = 6) and BDP-treated 
mice (n = 6) analyzed using flow cytometry.
www.nature.com/scientificreports/
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aromaticivorans-infected mice23, and E. coli-infected mice24 on this level. We hypothesize that our mouse model 
may be modified if genetic predisposition factors are also taken into account. For this purpose, the immunization 
of BDP in genetically susceptible mice38,39 will be performed in further studies.
Figure 4. More activated phenotype of CD4 and CD8 T cells in the liver after BDP immunization. (a) Flow 
cytometry analysis of CD44 and CD62L expression levels in liver CD4 (CD3+NK1.1−CD4+CD8−) and CD8 T 
cell (CD3+NK1.1−CD8+CD4−) subsets from adjuvant- (Adju) and BDP-treated mice (left panel); percentage 
analysis of central memory (CD44highCD62Lhigh), effector memory (CD44highCD62Llow) and naïve T cells 
(CD44lowCD62Lhigh) (right panel) (n = 9 for Adju and n = 9 for BDP). (b) Flow cytometry analysis of liver IFN-
γ+ CD4 and CD8 T cells (gated from CD3+NK1.1−) from adjuvant- (Adju) and BDP-treated mice (left panel); 
percentage analysis of IFN-γ+ CD4 and CD8 T cells (right panel) (n = 9 for Adju and n = 9 for BDP).
www.nature.com/scientificreports/
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Other factors related to PBC are gender and age. Some studies have shown organ-specific autoimmune lesions 
can occur spontaneously in senescent C57BL/6 mice, especially in female mice40,41. This is consistent with epi-
demiological survey of PBC patients1–3,42,43. However, in these spontaneous cholangitis mice, the autoimmune 
lesions first appeared in 6-month-old mice even for female mice. And the previous researches were focused on 
histologic study and circulating autoantibodies of IgG40,41. In our BDP-immunization model, the autoimmune 
cholangitis was detected in 12-week-old mice. Importantly, we detected high levels of AMAs, which are hallmarks 
of PBC. Concerning gender factor, we found that male mice was difficult to induce autoimmune cholangitis, 
which was consistent with the female predominance of PBC. Though we report the new liver-specific PBC mouse 
model, the mechanism of gender bias for autoimmune diseases is unclear.
A vigorous anti-viral T cell response is required for successful hepatitis viral clearance, whereas persistent 
viral infection is typically associated with weak T cell activation44,45. In addition, T cells are also accounted for 
Figure 5. Enhanced GC response in the spleen after BDP immunization. (a) GC B cells 
(CD3−CD19+IgD−Fas+GL7+) in the spleens of adjuvant- (Adju) and BDP-treated mice analyzed using flow 
cytometry (left panel). (b) Percentage and total number analysis of splenic GC B cells (n = 6 for Adju and n = 6 
for BDP). (c) Splenic plasmablasts (CD3−CD19+CD138hiB220lo) of adjuvant- (Adju) and BDP-treated mice 
analyzed using flow cytometry. (d) Percentage and total number analysis of splenic plasmablasts (n = 6 for Adju 
and n = 6 for BDP).
Figure 6. Increased serum AMA levels after BDP immunization. (a–c) Serum levels of AMAs against 
recombinant proteins of PDC-E2, BCOADC-E2, and OGDC-E2 analyzed via ELISA at a wave-length of 
450 nm.
www.nature.com/scientificreports/
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the progression of several autoimmune liver diseases46. Moreover, T cells participate in other disorders and inju-
ries of the liver, such as ischemia-reperfusion injury47, nonalcoholic steatohepatitis48, and liver cancers49. In our 
model, T lymphocytes are activated and increased in number, with an increased ability for inflammatory cytokine 
secretion, which also addressed the critical role of T cells in the pathogenesis of PBC. Compare with other mouse 
models of PBC, we would see that unbalanced T cell response is a common phenomenon, which appears in the 
dnTGFβRII mice, the IL-2Rα−/− mice, and the 2-OA-BSA-immunized mice17,20,25,50–52.
Tregs are essential for the maintenance of homeostasis and self-tolerance in various organs, including the 
liver53. Treg deficiency or defects will lead to the spontaneous development of various systemic or organ-specific 
autoimmune diseases, whereas the reconstitution of functional Tregs prevents disease development54,55. Tregs 
play pivotal roles in controlling various liver diseases via the suppression of effector T cell function and cytokine 
production, and the balance of effector and regulatory T cells always dictates the outcome of various liver dis-
eases56,57. Interestingly, in the present mouse model, both the liver and spleen exhibited a reduced Treg percent-
age, which may be involved in the further activation of T cells. The mechanism of the decreased Treg percentage 
associated with more severe inflammation is unclear, but this phenomenon is in consistent with other PBC mouse 
models, such as the dnTGF-βRII mice and IL-2Rα−/− mice20,58–60. Importantly, in patients with PBC and even the 
first relatives of them, Treg deficiency has also been determined61,62.
GCs develop in response to antigen stimulation and comprise the sites in which B cells undergo clonal expan-
sion during immune responses. In GCs, rapidly proliferating B cells form foci and undergo somatic hypermu-
tation and affinity-based selection, which eventually produces high-affinity antibodies63. GCs are critical for 
humoral immunity to protect against various infectious diseases; however, aberrant GC responses are associated 
with numerous autoimmune diseases, such as systemic lupus erythematosus64, Sjögren’s syndrome65, rheumatoid 
arthritis66,67, autoimmune thyroid disease68, and PBC69,70. In the present mouse model, enhanced GC responses, 
as well as increased titers of AMAs were noted. Thus, it is indicated that in our study, bile duct antigens stimulate 
the generation of abnormal GCs, where autoreactive B cells are generated and expanded, which promotes autoan-
tibody secretion and aggravates liver damage. Future studies should examine gender differences and provide a 
more robust analysis of innate and adaptive immunity69,71,72.
In summary, we report a novel PBC mouse model in which the liver tolerance is broken down by syngeneic 
BDP immunization, which leads to an abnormal activation of the immune system in the liver and, initiates an 
autoimmune response resembling that of PBC patients. However, we should state here that no granulomas and 
bile duct damage were observed in this mouse model, and whether a female bias appears in this model still needs 
further investigation.
Methods
Mice. Wild-type female mice from a C57BL/6 background were purchased from the Shanghai SLAC lab-
oratory animal center (SLAC, Shanghai, China). All mice were maintained in the laboratory animal center of 
the University of Science and Technology of China in specific pathogen-free conditions. The mice were treated 
according to the Guide for the Care and Use of Laboratory Animals of the University of Science and Technology 
of China. All experimental protocols in this study were approved by the Institute of Immunology, University of 
Science and Technology of China.
BDP isolation. For BDP isolation, the livers of 8- to 12-week-old mice were perfused in situ through the 
portal vein via collagenase IV (Sigma-Aldrich, St. Louis, Missouri, USA) for 10 min. The liver was then carefully 
cut and brushed with a soft toothbrush until the whole bile duct tree was clearly visualized. The bile duct tree 
was placed in collagenase IV (Sigma-Aldrich) and shaken for 10 min to separate the adhering hepatocytes. After 
washing in phosphate-buffered saline (PBS) for 3 times, the bile duct tree was thoroughly cut and homogenized in 
PBS via an ultrasonic disruptor (Xinzhi, Ningbo, China). After centrifugation at 12,000 × g and 4 °C for 5 min, the 
supernatant was collected, and the protein concentration was determined using a BCA protein assay kit (Thermo 
Fisher Scientific, Waltham, MA, USA).
BDP immunization protocol. Seven-or eight-week-old mice (SLAC, Shanghai, China) were used for BDP 
immunization. BDP at a concentration of 4000 µg/ml was emulsified with an equal volume of complete Freund’s 
adjuvant (CFA) purchased from Sigma-Aldrich. Following successful emulsification, 200 µl BDP-CFA emul-
sion were subcutaneously injected at multiple points on the back of a mouse. This BDP-CFA emulsion was used 
for 3 treatments. BDP was subsequently emulsified with incomplete Freund’s adjuvant (IFA) purchased from 
Sigma-Aldrich. This method and dose were the same as BDP-CFA. The BDP-IFA emulsion was used only in the 
last treatment. One week after the BDP-IFA treatment, the mice were sacrificed and analyzed. Control mice were 
treated via the emulsion of CFA or IFA with an equal volume of 0.9% NaCl solution or SIEP, and the injection 
dose and volume were the same as the experimental group (Fig. S4).
SIEP isolation. For SIEP isolation, the small intestines were cut off and opened to clear out the faeces with 
PBS. The small intestines were subsequently cut into 1-cm fragments in 30 mM EDTA and shaken at 37 °C for 
10 min. The supernatants were transferred to cold PBS and centrifuged at 500 × g for 5 min. The pellets that 
contained intestinal crypt cells were subsequently collected and homogenized in PBS via an ultrasonic disruptor 
(Xinzhi). After centrifuging at 12000 × g and 4 °C for 5 min, the supernatant was collected, and the protein con-
centration was determined using a BCA protein assay kit (Thermo Fisher Scientific).
Flow cytometry. MNCs from the liver, spleen, and mLNs were isolated as previously described25. The 
method for MNC isolation from dLNs and pLNs was the same as that for mLNs.
For staining cell surface markers, isolated MNCs were treated with anti-CD16/32 (Biolegend, San Diego, 
CA, USA) for 15 min, and subsequently incubated for 20 min with fluorescent antibodies. The fluorescent 
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antibodies included FITC-conjugated anti-I-A/I-E (M5/114.15.2), anti-CD3 (17A2); PE-conjugated anti-CD25 
(PC61); PerCP/Cy5.5-conjugated anti-CD11c (N418), anti-GL7 (GL7); PE/Cy7-conjugated anti-NK1.1 (PK136), 
anti-CD19 (6D5); APC/Cy7-conjugated anti-CD4 (GK1.5), anti-IgD (11–26 c.2a), anti-CD4 (GK1.5); and Pacific 
Blue-conjugated anti-CD3 (17A2), anti-NK1.1 (PK136), anti-CD45R (RA3-6B2), which were all purchased from 
Biolegend. PE-conjugated anti-CD138 (281-2) and V500-conjugated anti-CD8α (53-6.7) were purchased from 
BD Biosciences (Franklin Lakes, New Jersey, USA). Alexa 488-conjugated anti-CD95 (15A7) was purchased from 
eBioscience (San Diego, CA, USA).
For Foxp3 staining, a Foxp3 detection kit (eBioscience) was used according to the manufacturer’s instructions. 
Alexa 647-conjugated Foxp3 (150D, Biolegend) was used for intracellular staining.
For IFN-γ staining, MNCs were suspended in RPMI 1640 medium (Thermo Fisher Scientific) with 10% 
fetal bovine serum (Millipore, Billerica, MA, USA) and stimulated with a Cell Stimulation Cocktail (eBiosci-
ence) at 37 °C for 4 h. The MNCs were subsequently fixed with a fixation/permeabilization buffer kit from BD 
Biosciences according to the manufacturer’s instructions. PE or PE/Cy7-conjugated anti-IFN-γ (XMG1.2) anti-
body (Biolegend) was used for intracellular staining.
A FACSVerse flow cytometer (BD Biosciences) was used to collect the flow cytometry data, and data analysis 
was performed using Flowjo software (Tree Star, Ashland, OR, USA).
Histology. Fresh tissues were fixed in 4% paraformaldehyde for 48 h, and subsequently embedded with par-
affin. The samples were cut into 4-μm sections and deparaffinated at 60 °C for 40 min. The sections were sub-
sequently stained with H&E and viewed under a light microscope as previously reported58. To specify BECs, 
immunohistochemical staining of cytokerin-19 was assessed by staining with anti-cytokeratin 19 (Abcam, 
Cambridge, UK) and visualized with a ChemMate EnVision Detection Kit (Dako, Produktionsvej, Denmark)73.
Enzyme-linked immunosorbent assay (ELISA) for analysis of AMAs. Recombinant PDC-E2, 
BCOADC-E2, and OGDC-E2 were coated overnight at 4 °C at a concentration of 15 μg/ml in a 96-well-plate. 
The plates were subsequently blocked with 3% skimmed milk for 1 h. Serum diluted 1/20 was added to the plates 
for 1 h. Anti-mouse IgG peroxidase (Sigma-Aldrich) was subsequently added to the plates for 1 h. Finally, a TMB 
Substract Reagent Set (BD Biosciences) was added for 10 min. Following the addition of stop solutions (BD 
Biosciences), the optical density was read at 450 nm.
Statistical analysis. All data are representative of at least 3 replicates and are presented as the mean ± stand-
ard deviation (SD). Mann-Whitney U-test was used to analyze the differences between two groups. The confi-
dence interval is 95%. The differences were significant if the p value was less than 0.05: *p < 0.05, **p < 0.01, and 
***p < 0.001. All data are analyzed using a GraphPad Prism software (GraphPad Software, Inc., San Diego, CA, 
USA).
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